Roche Foundation Medicine is pleased to announce the launch of FoundationOne®Liquid, our new second-generation liquid biopsy test for patients with solid tumours.56

Granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA) in April 2018, FoundationOne®Liquid builds on the technology of FoundationACT® and now includes more than 70 genes and genomic biomarkers for microsatellite instability (MSI).56
Maintaining its clinically practical single blood draw of two tubes of blood sampling method, FoundationOne®Liquid aims to be the first FDA-approved liquid biopsy assay to incorporate multiple companion diagnostics (CDx) and multiple biomarkers to inform the use of targeted oncology therapies, including immunotherapies.56,57
The planned launch of FoundationOne®Liquid globally is this year and will be available to order for your patients soon so kindly watch this space.
For more information, please contact your local Roche Foundation Medicine Customer Service team by clicking here. Alternatively, you can reach us at APAC.foundation@roche.com.
FoundationOne®Liquid FAQs